Working… Menu

Laser Treatment in Early Wound Healing to Promote Physiological Skin Remodeling

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03253484
Recruitment Status : Unknown
Verified August 2017 by Katrine Elisabeth Karmisholt, Bispebjerg Hospital.
Recruitment status was:  Not yet recruiting
First Posted : August 18, 2017
Last Update Posted : August 18, 2017
Information provided by (Responsible Party):
Katrine Elisabeth Karmisholt, Bispebjerg Hospital

Brief Summary:
The primary objective of this study is to explore the potential clinical effect of targeting surgical wounds in all three wound healing phases by non ablative fractional laser (NAFL) to reduce scar formation in a randomized controlled trial. Thus, NAFL will be applied during 1) inflammation phase (0-3 days) as represented by NAFL-treatment adjacent to surgical wounding, 2) proliferation phase (4-21 days) by NAFL-treatment immediately after suture removal and 3) remodeling phase (21 days-1 year) by NAFL-treatment six weeks after surgery.

Condition or disease Intervention/treatment Phase
Scar Improvement by Laser Radiation: NAFL-treatment Not Applicable

Detailed Description:
This is a prospective, randomized, controlled, assessor - blinded, intra-individual trial comparing laser exposed skin lesions to untreated control skin lesions in a split scar set-up to investigate efficacy. The study will be performed on patients undergoing an excision at Bispebjerg Dermatological Department. One randomly allocated part of each included wound will receive three NAFL-treatments and the other part will serve as untreated control wound. Scars will be evaluated clinically on-site by blinded evaluator immediately before third treatment and 3 months after NAFL-treatments. The clinical data will be supplemented by blinded photo-evaluation, patients' evaluation and non-invasive measurements.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: split scar study
Masking: Single (Outcomes Assessor)
Masking Description: the outcome assessor will not know which side is the treated side of scar
Primary Purpose: Treatment
Official Title: Laser Treatment in Early Wound Healing to Promote Physiological Skin Remodeling
Estimated Study Start Date : August 18, 2017
Estimated Primary Completion Date : January 31, 2018
Estimated Study Completion Date : January 31, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: NAFL-treated wounds
NAFL treated wounds
Radiation: NAFL-treatment
non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation

No Intervention: Control
untreated control wound

Primary Outcome Measures :
  1. Clincial evaluation on Patient observer scar assessement scale (POSAS) [ Time Frame: 3 months followup ]
    validated scar scale

Secondary Outcome Measures :
  1. Photoevaluation on visual analogue scale [ Time Frame: 3 months follow-up ]
    3 independent dermatologists will evaluate on VAS

  2. Reflectance measurement [ Time Frame: 3 months followup ]
    measurement of erythema and pigment

  3. Clinical evaluation on Vancouver Scar Scale [ Time Frame: 3 months followup ]
    validated scar scale

  4. Clincial evaluation on Patient observer scar assessement scale (POSAS) [ Time Frame: 1month follow-up ]
    validated scar scale

  5. Clinical evaluation on Vancouver Scar Scale [ Time Frame: 1month follow-up and ]
    validated scar scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • o Subjects referred to excision of either benign, pre malignant or malignant non-melanoma skin cancer (NMSC) lesions.

    • The length of postoperative wound should be estimated to minimum 2.5 cm and may be located on any region of the body
    • Minimum 18 years old
    • Presenting full medical record report at study initiation
    • Fitzpatrick skin type I-III
    • Non-smokers
    • Written informed consent obtained from subject
    • Understanding of investigation procedures and willingness to abide to all procedures during the course of the investigation

Exclusion Criteria:

  • o History of or presenting with a keloid scar

    • A subject with a systemic disease not yet stabilized
    • If the patient is pregnant
    • Visible recent sun exposure in test area
    • Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study
    • Current use of topical treatment and lack of willingness to refrain from future use of topical treatment, such as i.e. silicone products, that potentially can interfere with the test results
    • Unable to follow the outlined study protocol

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Katrine Elisabeth Karmisholt, MD, Bispebjerg Hospital Identifier: NCT03253484     History of Changes
Other Study ID Numbers: H-17012492
First Posted: August 18, 2017    Key Record Dates
Last Update Posted: August 18, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Katrine Elisabeth Karmisholt, Bispebjerg Hospital:
scar NAFL laser